Implante transcateter da válvula aórtica (TAVI) em pacientes com valva aórtica bicúspide versus tricúspide: um estudo retrospectivo comparativo / Transcatheter aortic valve implantation (TAVI) in patients with bicuspid versus tricuspid aortic valve: a comparative retrospective study

INTRODUÇÃO: A válvula aórtica bicúspide (BAV) ocorre em até 6% dos pacientes com estenose aórtica importante. Sua presença pode refletir um desafio para TAVI uma vez que pacientes com BAV podem possuir maiores diâmetros do anel valvar, calcificação acentuada dos folhetos e dilatação da aorta ascendente. O número crescente de TAVI nessa população torna imperativo um aprofundamento na investigação de seus resultados e desfechos clínicos. MÉTODOS: Retrospectivo, unicêntrico e observacional. Realizamos uma revisão de banco de dados e selecionamos pacientes submetidos a TAVI no período de novembro de 2020 a janeiro de 2024. O objetivo deste estudo é avaliar a incidência e resultados imediatos na população com BAV comparativamente aos pacientes com valva tricúspide. Para isso, foram coletados dados clínicos e demográficos, bem como informações sobre complicações e desfechos intrahospitalares após TAVI em ambas as populações, segundo o VARC 3. A análise dos dados foi realizada utilizando estatística descritiva e comparativa (Teste T de Student), com intuito de verificar se há diferenças significativas em desfechos entre as populações. RESULTADOS: De um total de 174 pacientes, 33 deles apresentaram BAV, resultando em uma incidência de 18,96%. A análise estatística não evidenciou diferença significativa nos dados de base de ambas as populações. Média de idade entre o grupo BAV (75,84 ± 8,19 anos) e o grupo tricúspide (78,61 ± 6,32 anos), com um p-valor não significativo de p 0,243. O STS score médio foi de 3,14 ± 1,86% no grupo BAV e 3,47 ± 1,97% no grupo tricúspide; p 0,12. Em relação ao procedimento, houve diferença significativa na necessidade de pré-dilatação entre os grupos, sendo necessária em 25 dos 33 casos de bicúspide (75,75%) e 71 dos 141 casos de tricúspide (50,35%) (p 0,008). Porém, não foi evidenciada diferença significativa no gradiente ventrículo esquerdo e aorta pós-procedimento de 4,53 ± 3,04 vs 5,33 ± 4,46; p 0,233, de bicúspide e tricúspide respectivamente; nem no tempo de permanência hospitalar pós procedimento 2,63 ± 2,11 vs 3,03 ± 4,29; p 0,439. Não foi observado também diferença significativa em relação a necessidade de marcapasso definitivo, refluxo paravalvular ou complicações hemorrágicas e vasculares. CONCLUSÃO: Com base nos resultados, não foi observada diferença significativa nos desfechos entre os pacientes com BAV e tricúspide. Estes achados sugerem que a TAVI é um tratamento seguro e eficaz para pacientes com BAV. No entanto, são necessários estudos adicionais com amostras mais amplas para confirmar esses resultados.

Primary Prevention of Cardiovascular Disease at Community Clinics in the State of Sao Paulo, Brazil: Results from the Epidemiological Information Study of Communities.

Background: Primary prevention of cardiovascular disease (CVD) remains a major challenge, especially in communities of low- and middle-income countries with poor medical assistance influenced by distinct local, financial, infrastructural, and resource-related factors. Objective: This a community-based study aimed to determine the proportion and prevalence of uncontrolled cardiovascular risk factors (CRF) in Brazilian communities. Methods: The EPICO study was an observational, cross-sectional, and community clinic-based study. Subjects were living in Brazilian communities and were of both sexes and ≥18 years old, without a history of a stroke or myocardial infarction but presenting at least one of the following cardiovascular risk factors: hypertension, diabetes mellitus and hypercholesterolemia. The study was carried out in Brazil, including 322 basic health units (BHU) in 32 cities. Results: A total of 7,724 subjects with at least one CRF were evaluated, and one clinical visit was performed. Mean age was 59.2 years-old (53.7% were >60 years old). A total of 66.7% were women. Of the total, 96.2% had hypertension, 78.8% had diabetes mellitus type II, 71.1% had dyslipidemia, and 76.6% of patients were overweight/obese. Controlled hypertension (defined by <130/80 mmHg or <140/90 mmHg) was observed in 34.9% and 55.5% patients among respective criteria, the rates of controlled blood glucose in patients taking antidiabetic medications was 29.5%, and among those with documented dyslipidemia who received any lipid-lowering medication, only 13.9% had LDL-c on target. For patients presenting three CRF less than 1.9% had LDL-c < 100 mg/dL once their BP and blood glucose were on target. High education level as associated with blood pressure (BP) target of less than 130 / 80mm Hg. The glucose and LDL-c levels on target were associated with the presence of hypertension and diabetes mellitus. Conclusion: In Brazilian community clinics, regarding most patients in primary prevention, the CRF such as BP, blood glucose, and lipid levels are poorly controlled, with a majority of patients not achieving guidelines/recommendations.

Primary prevention of cardiovascular disease at community clinics in the state of Sao Paulo, Brazil: results from the epidemiological information study of communities

BACKGROUND: Primary prevention of cardiovascular disease (CVD) remains a major challenge, especially in communities of low- and middle-income countries with poor medical assistance influenced by distinct local, financial, infrastructural, and resource-related factors. OBJECTIVE: This a community-based study aimed to determine the proportion and prevalence of uncontrolled cardiovascular risk factors (CRF) in Brazilian communities. METHODS: The EPICO study was an observational, cross-sectional, and community clinic-based study. Subjects were living in Brazilian communities and were of both sexes and ≥18 years old, without a history of a stroke or myocardial infarction but presenting at least one of the following cardiovascular risk factors: hypertension, diabetes mellitus and hypercholesterolemia. The study was carried out in Brazil, including 322 basic health units (BHU) in 32 cities. RESULTS: A total of 7,724 subjects with at least one CRF were evaluated, and one clinical visit was performed. Mean age was 59.2 years-old (53.7% were >60 years old). A total of 66.7% were women. Of the total, 96.2% had hypertension, 78.8% had diabetes mellitus type II, 71.1% had dyslipidemia, and 76.6% of patients were overweight/obese. Controlled hypertension (defined by <130/80 mmHg or <140/90 mmHg) was observed in 34.9% and 55.5% patients among respective criteria, the rates of controlled blood glucose in patients taking antidiabetic medications was 29.5%, and among those with documented dyslipidemia who received any lipid-lowering medication, only 13.9% had LDL-c on target. For patients presenting three CRF less than 1.9% had LDL-c < 100 mg/dL once their BP and blood glucose were on target. High education level as associated with blood pressure (BP) target of less than 130 / 80mm Hg. The glucose and LDL-c levels on target were associated with the presence of hypertension and diabetes mellitus. CONCLUSION: In Brazilian community clinics, regarding most patients in primary prevention, the CRF such as BP, blood glucose, and lipid levels are poorly controlled, with a majority of patients not achieving guidelines/recommendations.

Ablação septal por radiofrequência no tratamento da cardiomiopatia hipertrófica obstrutiva: experiência de serviço terciário / Radiofrequency septal ablation in the treatment of obstructive hypertrophic cardiomyopathy: experience of a tertiary service

INTRODUÇÃO: A cardiomiopatia hipertrófica obstrutiva (CMHO) pode estar associada a sintomas limitantes de qualidade de vida, refratários à terapêutica otimizada. A terapia de redução septal (TRS) está indicada nestes pacientes, quando há gradiente de via de saída do ventrículo esquerdo (GVSVE)≥ 50mmHg. A miectomia septal e a ablação septal com álcool são as formas de TRS indicadas por diretrizes. Um novo método tem sido desenvolvido: a ablação septal por radiofrequência (ASRF), utilizando-se os mesmos cateteres dos estudos eletrofisiológicos invasivos. Descrevemos, neste estudo uma série de casos de pacientes que foram submetidos a esta nova técnica. MÉTODOS: Estudo observacional, do tipo coorte histórica por análise de prontuários. Foram selecionados pacientes com idade maior que 18 anos, submetidos a abordagem invasiva para redução de GVSVE por ASRF, de 01 de janeiro de 2019 a 31 de dezembro de 2022, com pelo menos 1 ano de acompanhamento. RESULTADOS :Foram analisados 28 pacientes, sendo 6 (21,4%) masculinos, com média de idade de59 anos (DP ± 10 anos), média de GVSVE sistólico de 89 mmHg (DP ± 33,9mmHg) e todos com classe funcional III/IV. Dados clínicos dos pacientes estão listados na tabela 1. Houve queda do GVSVE em24 pacientes (85,7%) após 1 ano de acompanhamento,ficando com valor final de GVSVE em média de 34mmHg (DP ± 33,3mmHg). Na sala de procedimento, imediatamente após a aplicação de RF, observou-se menor queda do GVSVE, ficando valor de GVSVE em torno de 40mmHg DP ± 30,5mmHg.

Role of B lymphocytes in the infarcted mass in patients with acute myocardial infarction

Introduction: Almost 20% of patients with acute myocardial infarction (MI) develop heart failure, even when early reperfused [1]. Left ventricular remodeling seems related to the size of myocardial infarction and timely reperfusion, as well as to the inflammatory responses and residual ischemia [2]. Experimental studies suggested that B lymphocytes may influence the myocardial infarcted mass [3], although there are few data about the role of these cells in humans. Furthermore, a possible atheroprotective role for B1 lymphocytes has been proposed based on the production of interleukin 10 (IL-10) and natural antibodies, which may switch the proinflammatory response to more appropriate healing, promoting cell recovery and the clearance of apoptotic cellular debris [4]. On the other hand, classic B lymphocytes or B2 cells are linked to progression of atherosclerosis, possibly by their interaction with CD4+ T lymphocytes [4]. In 2011, Griffin and colleagues proposed CD19+CD20+CD43+CD70- lymphocyte cells as the human B1 phenotype, and these cells spontaneously produced IgM and IL-10 [5]. However, according to the presence or absence of the CD11b on the surface of these cells, the capacity of IgM production and activation Stem cells in blood marrow differentiate in T or B lymphocyte, according to the presence of CD3 or CD19, respectively. Lymphocyte final maturation takes place in thymus for T cells; or in spleen and lymphatic tissue for classic B cells. B1 lymphocytes are well described in experimental studies. These cells are notorious for their capacity of spontaneous production of IgM and according to the presence of the CD11b, two distinct subtypes are recognized: CD11b- B1 lymphocytes, producing IgM, and CD11b+ B1 lymphocytes, related to the expansion of CD4+ T lymphocytes.

Role of B lymphocytes in the infarcted mass in patients with acute myocardial infarction.

Despite early reperfusion, patients with ST segment elevation myocardial infarction (STEMI) may present large myocardial necrosis and significant impairment of ventricular function. The present study aimed to evaluate the role of subtypes of B lymphocytes and related cytokines in the infarcted mass and left ventricular ejection fraction obtained by cardiac magnetic resonance imaging performed after 30 days of STEMI. This prospective study included 120 subjects with STEMI submitted to pharmacoinvasive strategy. Blood samples were collected in subjects in the first (D1) and 30th (D30) days post STEMI. The amount of CD11b+ B1 lymphocytes (cells/ml) at D1 were related to the infarcted mass (rho = 0.43; P=0.033), measured by cardiac MRI at D30. These B1 cells were associated with CD4+ T lymphocytes at D1 and D30, while B2 classic lymphocytes at day 30 were related to left ventricular ejection fraction (LVEF). Higher titers of circulating IL-4 and IL-10 were observed at D30 versus D1 (P=0.013 and P<0.001, respectively). Titers of IL-6 at D1 were associated with infarcted mass (rho = 0.41, P<0.001) and inversely related to LVEF (rho = -0.38, P<0.001). After multiple linear regression analysis, high-sensitivity troponin T and IL-6 collected at day 1 were independent predictors of infarcted mass and, at day 30, only HDL-C. Regarding LVEF, high-sensitivity troponin T and high-sensitivity C-reactive protein were independent predictors at day 1, and B2 classic lymphocytes, at day 30. In subjects with STEMI, despite early reperfusion, the amount of infarcted mass and ventricular performance were related to inflammatory responses triggered by circulating B lymphocytes.

A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: rationale and design of the RIVER trial

Background The efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valves and atrial fibrillation or flutter remain uncertain. Design RIVER was an academic-led, multicenter, open-label, randomized, non-inferiority trial with blinded outcome adjudication that enrolled 1005 patients from 49 sites in Brazil. Patients with a bioprosthetic mitral valve and atrial fibrillation or flutter were randomly assigned (1:1) to rivaroxaban 20 mg once daily (15 mg in those with creatinine clearance <50 mL/min) or dose-adjusted warfarin (target international normalized ratio 2.0-30.); the follow-up period was 12 months. The primary outcome was a composite of all-cause mortality, stroke, transient ischemic attack, major bleeding, valve thrombosis, systemic embolism, or hospitalization for heart failure. Secondary outcomes included individual components of the primary composite outcome, bleeding events, and venous thromboembolism. Summary RIVER represents the largest trial specifically designed to assess the efficacy and safety of a direct oral anticoagulant in patients with bioprosthetic mitral valves and atrial fibrillation or flutter. The results of this trial can inform clinical practice and international guidelines.

Mid- to long-term clinical and echocardiographic outcomes after transcatheter aortic valve replacement with a new-generation, self-expandable system.

OBJECTIVES: The aim of the study was to evaluate mid- to late clinical and echocardiographic outcomes after transcatheter aortic valve replacement (TAVR) with Acurate neo™ (Boston Scientific, Boston, MA). BACKGROUND: TAVR is an established treatment for aortic stenosis (AS). Few data exist on mid- to long-term outcomes and durability after new-generation valves. METHODS: All consecutive patients (n = 104) who underwent Acurate neo™ implantation from 2012 to 2018 were included. Follow-up was systematically performed at 1, 6, 12, and 24 months and yearly thereafter. Outcomes were reported according to VARC-2, and structural valve deterioration (SVD) or bioprosthetic valve failure defined accordingly to new definitions. RESULTS: Mean age was 82 ± 5.4 years, 56.7% were female and the Society of Thoracic Surgeons score for mortality was 5.9 ± 4%. Patients were followed for a median of 3 years (1,092 days; IQR 1.5-4 years), and the maximum follow-up was 7 years. All-cause mortality values at 1 and 5 years were 8.5% and 40.5%, respectively. No relevant changes in mean gradient and orifice area occurred (7.9 ± 3.8 mmHg and 1.9 ± 0.3 cm2 at 1 year; 6.6 ± 2.1 mmHg and 1.8 ± 0.3 cm2 at 5 years), and there was a significant rate of paravalvular leaks resolution at 1, 2, and 3 years (p = .004; p < .001; p < .001, respectively). None of the patients had leaflet thrombosis or endocarditis. One patient developed SVD at 84 months. CONCLUSIONS: Acurate neo™ was associated with sustained echocardiographic results. Reassuring mid- to long-term outcomes was observed in this cohort of elderly patients with severe AS.

A randomized clinical trial to evaluate the efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valve and atrial fibrillation or flutter: Rationale and design of the RIVER trial.

The efficacy and safety of rivaroxaban in patients with bioprosthetic mitral valves and atrial fibrillation or flutter remain uncertain. DESIGN: RIVER was an academic-led, multicenter, open-label, randomized, non-inferiority trial with blinded outcome adjudication that enrolled 1005 patients from 49 sites in Brazil. Patients with a bioprosthetic mitral valve and atrial fibrillation or flutter were randomly assigned (1:1) to rivaroxaban 20 mg once daily (15 mg in those with creatinine clearance <50 mL/min) or dose-adjusted warfarin (target international normalized ratio 2.0-30.); the follow-up period was 12 months. The primary outcome was a composite of all-cause mortality, stroke, transient ischemic attack, major bleeding, valve thrombosis, systemic embolism, or hospitalization for heart failure. Secondary outcomes included individual components of the primary composite outcome, bleeding events, and venous thromboembolism. SUMMARY: RIVER represents the largest trial specifically designed to assess the efficacy and safety of a direct oral anticoagulant in patients with bioprosthetic mitral valves and atrial fibrillation or flutter. The results of this trial can inform clinical practice and international guidelines.

Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve.

BACKGROUND: The effects of rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve remain uncertain. METHODS: In this randomized trial, we compared rivaroxaban (20 mg once daily) with dose-adjusted warfarin (target international normalized ratio, 2.0 to 3.0) in patients with atrial fibrillation and a bioprosthetic mitral valve. The primary outcome was a composite of death, major cardiovascular events (stroke, transient ischemic attack, systemic embolism, valve thrombosis, or hospitalization for heart failure), or major bleeding at 12 months. RESULTS: A total of 1005 patients were enrolled at 49 sites in Brazil. A primary-outcome event occurred at a mean of 347.5 days in the rivaroxaban group and 340.1 days in the warfarin group (difference calculated as restricted mean survival time, 7.4 days; 95% confidence interval [CI], -1.4 to 16.3; P<0.001 for noninferiority). Death from cardiovascular causes or thromboembolic events occurred in 17 patients (3.4%) in the rivaroxaban group and in 26 (5.1%) in the warfarin group (hazard ratio, 0.65; 95% CI, 0.35 to 1.20). The incidence of stroke was 0.6% in the rivaroxaban group and 2.4% in the warfarin group (hazard ratio, 0.25; 95% CI, 0.07 to 0.88). Major bleeding occurred in 7 patients (1.4%) in the rivaroxaban group and in 13 (2.6%) in the warfarin group (hazard ratio, 0.54; 95% CI, 0.21 to 1.35). The frequency of other serious adverse events was similar in the two groups. CONCLUSIONS: In patients with atrial fibrillation and a bioprosthetic mitral valve, rivaroxaban was noninferior to warfarin with respect to the mean time until the primary outcome of death, major cardiovascular events, or major bleeding at 12 months. (Funded by PROADI-SUS and Bayer; RIVER ClinicalTrials.gov number, NCT02303795.).

Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve

BACKGROUND The effects of rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve remain uncertain. METHODS In this randomized trial, we compared rivaroxaban (20 mg once daily) with dose adjusted warfarin (target international normalized ratio, 2.0 to 3.0) in patients with atrial fibrillation and a bioprosthetic mitral valve. The primary outcome was a composite of death, major cardiovascular events (stroke, transient ischemic attack, systemic embolism, valve thrombosis, or hospitalization for heart failure), or major bleeding at 12 months. RESULTS A total of 1005 patients were enrolled at 49 sites in Brazil. A primary-outcome event occurred at a mean of 347.5 days in the rivaroxaban group and 340.1 days in the warfarin group (difference calculated as restricted mean survival time, 7.4 days; 95% confidence interval [CI], −1.4 to 16.3; P<0.001 for noninferiority). Death from cardiovascular causes or thromboembolic events occurred in 17 patients (3.4%) in the rivaroxaban group and in 26 (5.1%) in the warfarin group (hazard ratio, 0.65; 95% CI, 0.35 to 1.20). The incidence of stroke was 0.6% in the rivaroxaban group and 2.4% in the warfarin group (hazard ratio, 0.25; 95% CI, 0.07 to 0.88). Major bleeding occurred in 7 patients (1.4%) in the rivaroxaban group and in 13 (2.6%) in the warfarin group (hazard ratio, 0.54; 95% CI, 0.21 to 1.35). The frequency of other serious adverse events was similar in the two groups. CONCLUSIONS In patients with atrial fibrillation and a bioprosthetic mitral valve, rivaroxaban was noninferior to warfarin with respect to the mean time until the primary outcome of death, major cardiovascular events, or major bleeding at 12 months.

Mid- to long-term clinical and echocardiographic outcomes after transcatheter aortic valve replacement with a newgeneration, self-expandable system / Desfechos clínicos e ecocardiográficos de médio a longo prazo após a substituição da válvula aórtica transcateter com uma nova geração, sistema auto-expansível

Abstract Objectives: The aim of the study was to evaluate mid- to late clinical and echocardiographic outcomes after transcatheter aortic valve replacement (TAVR) with A curate neo™ (Boston Scientific, Boston, MA). Background: TAVR is an established treatment for aortic stenosis (AS). Few data exist on mid- to long-term outcomes and durability after new-generation valves. Methods: All consecutive patients (n = 104) who underwent A curate neo™ implantation from 2012 to 2018 were included. Follow-up was systematically performed at 1, 6, 12, and 24 months and yearly thereafter. Outcomes were reported according to VARC-2, and structural valve deterioration (SVD) or bioprosthetic valve failure defined accordingly to new definitions. Results: Mean age was 82 ± 5.4 years, 56.7% were female and the Society of Thoracic Surgeons score for mortality was 5.9 ± 4%. Patients were followed for a median of 3 years (1,092 days; IQR 1.5­4 years), and the maximum follow-up was 7 years. All-cause mortality values at 1 and 5 years were 8.5% and 40.5%, respectively. No relevant changes in mean gradient and orifice area occurred (7.9 ± 3.8 mmHg and 1.9 ± 0.3 cm2 at 1 year; 6.6 ± 2.1 mmHg and 1.8 ± 0.3 cm2 at 5 years), and there was a significant rate of paravalvular leaks resolution at 1, 2, and 3 years (p = .004; p < .001; p < .001, respectively). None of the patients had leaflet thrombosis or endocarditis. One patient developed SVD at 84 months. Conclusions: A curate neo™ was associated with sustained echocardiographic results. Reassuring mid- to long-term outcomes was observed in this cohort of elderly patients with severe AS.

Amiloidose cardíaca ou cardiomiopatia hipertrófica? estudo genético positivo simplifica ou dificulta o diagnóstico? / Cardiac amyloidosis or hypertrophic cardiomyopathy? Does positive genetic study simplify or hinder the diagnosis?

INTRODUÇÃO: Em pacientes com hipertrofia ventricular concêntrica, o diagnóstico diferencial inclui principalmente Cardiomiopatia Hipertrófica, Doença de Fabry e Amiloidose Cardíaca. Por estas doenças terem, em alguns casos, etiologia genética, o reconhecimento de uma mutação patológica pode ser considerada o elemento principal para o diagnóstico diferencial. Descrevemos um caso em que o estudo genético não foi decisivo para o diagnóstico. Relato de caso: 46 anos, masculino, assintomático até há 3 anos, quando apresentou subitamente palpitação com pulso irregular. Evoluiu com dispneia e dor precordial progressiva aos esforços e parestesia em membro superior direito de longa duração. Exame físico com sopro sistólico em bordo esternal esquerdo com aumento após manobra de Valsalva. ECG: ritmo sinusal sobrecarga ventricular esquerda, com alteração de repolarização ventricular. Ecocardiograma: espessura septal 25mm parede lateral: 11mm, fração de ejeção de 68%, gradiente medioventricular de 56mmHg com aumento para 80mmHg com manobra de Valsalva. Foi feito diagnóstico de Cardiomiopatia Hipertrófica Obstrutiva. No screening familiar, identificado filho com 14 anos com o mesmo diagnóstico. Foi solicitado estudo genético para Amiloido se pela queixa compatível com neuropatia, que foi positivo para a mutação no gene da transtirretina Val142I1e patogênica, em heterozigose. A cintilografia com pirofosfato foi negativa para amiloidose (Grau 1). Foi indicada ablação septal com radiofrequência com melhora significativa dos sintomas e melhora da restrição funcional no teste cardiopulmonar (VO2 pico 60% do predito antes e 76% após ablação). Realizou painel NGS para CMH que evidenciou além da variante patogênica no gene da TTR, outra mutação no gene da tropomiosina (TPM1). Discussão e conclusão: o encontro de uma mutação patogênica no gene da transtirretina geralmente direciona o diagnóstico para amiloidose. No entanto, no presente caso, o fenótipo era compatível com CMH por haver obstrução intraventricular e um familiar jovem com fenótipo semelhante. O painel para CMH realizado posteriormente, evidenciou a presença de duas mutações, uma no gene da Tropomiosina e uma no gene da Transtirretina, portanto configuranda situação de genótipo e fenótipo de CMH e portador do gene sem fenótipo de Amiloidose. Concluimos que o estudo genético para uma mutação específica apesar de defini claramente a presença da mutação, não esclarece ser esta a causa do fenótipo.

Comparison of computed tomography venography and intravascular ultrasound in screening and classification of iliac vein obstruction in patients with chronic venous disease.

OBJECTIVE: To investigate power of computed tomography venography (CTV) to identify and characterize iliac vein obstruction (IVO) compared with intravascular ultrasound (IVUS) examination in highly symptomatic patients with chronic venous disease (CVD). METHODS: CVD CEAP C3-6 limbs with visual analog scale for pain score of greater than 3 and/or Venous Clinical Severity Scale of greater than 8 were prospectively investigated with CTV and IVUS examination. The segment of maximum IVO was verified and categorically classified: group I, 0% to 49%; group II, 50% to 79%; and group III, 80% or greater. The CTV's screening power to detect the point and degree of maximum IVO was compared with IVUS. RESULTS: The CTV point of maximum IVO was 80% in the left limb, 10% in the right limb, 10% bilaterally; 2% in the inferior vena cava; 91% in the common iliac vein (CIV) confluence (41.6% below the CIV confluence, 34.5 at the CIV confluence, and 23.9% above the CIV confluence); 7% at the external iliac vein (kappa index 0.841; P < .001, when compared with IVUS). The distal venous segment considered free of obstruction was above inguinal ligament: 68% (CIV, 47%; external iliac vein, 21%) 32% below the inguinal ligament (common femoral vein, 26%; deep femoral vein, 6%) (kappa index 0.671; P = .023, when compared with IVUS). The power of CTV to detect an IVO of 50% or greater (groups II and III) when compared with IVUS achieved a sensitivity and specificity ratio of 94.0% and 79.2%, respectively. The positive predictive value was 94%, the negative predictive value was 79.1%, accuracy was 86.7% (kappa, 0.733), and interobserver agreement was 92.1% (95% confidence interval, 87.1-97.7; kappa, 0.899). CONCLUSIONS: CTV is a powerful screening method in determining the precise point of compression and classifying IVO in limbs with symptomatic CVD when compared with IVUS. The prevalence of an obstruction above the iliac vein confluence is significant and should be considered in iliac vein stenting treatment strategy. The tomographic classification system proposed here may help to define the optimum technique of treatment, prognosis, and comparison of outcome results.

Comparison of computed tomography venography and intravascular ultrasound in screening and classification of iliac vein obstruction in patients with chronic venous disease

Objective: To investigate power of computed tomography venography (CTV) to identify and characterize iliac vein obstruction (IVO) compared with intravascular ultrasound (IVUS) examination in highly symptomatic patients with chronic venous disease (CVD). Methods: CVD CEAP C3-6 limbs with visual analog scale for pain score of greater than 3 and/or Venous Clinical Severity Scale of greater than 8 were prospectively investigated with CTV and IVUS examination. The segment of maximum IVO was verified and categorically classified: group I, 0% to 49%; group II, 50% to 79%; and group III, 80% or greater. The CTV's screening power to detect the point and degree of maximum IVO was compared with IVUS. Results: The CTV point of maximum IVO was 80% in the left limb, 10% in the right limb, 10% bilaterally; 2% in the inferior vena cava; 91% in the common iliac vein (CIV) confluence (41.6% below the CIV confluence, 34.5 at the CIV confluence, and 23.9% above the CIV confluence); 7% at the external iliac vein (kappa index 0.841; P < .001, when compared with IVUS). The distal venous segment considered free of obstruction was above inguinal ligament: 68% (CIV, 47%; external iliac vein, 21%) 32% below the inguinal ligament (common femoral vein, 26%; deep femoral vein, 6%) (kappa index 0.671; P » .023, when compared with IVUS). The power of CTV to detect an IVO of 50% or greater (groups II and III) when compared with IVUS achieved a sensitivity and specificity ratio of 94.0% and 79.2%, respectively. The positive predictive value was 94%, the negative predictive value was 79.1%, accuracy was 86.7% (kappa, 0.733), and interobserver agreement was 92.1% (95% confidence interval, 87.1-97.7; kappa, 0.899). Conclusions: CTV is a powerful screening method in determining the precise point of compression and classifying IVO in limbs with symptomatic CVD when compared with IVUS. The prevalence of an obstruction above the iliac vein confluence is significant and should be considered in iliac vein stenting treatment strategy. The tomographic classification system proposed here may help to define the optimum technique of treatment, prognosis, and comparison of outcome results. (J Vasc Surg: Venous and Lym Dis 2019;-:1-10.) Keywords: Iliac vein obstruction; Computed tomography Venography; Intravascular ultrasound; May-Thuner syndrome; Cockett syndrome; Classification

Compressão extrínseca de coronária direita anômala corrigida e elegibilidade para atividade física / Corrected anomalous right coronary extrinsic compression and eligibility for physical activity

RELATO DE CASO: FAD, 34 anos, masculino, branco, esportista, corredor de rua (3 a 4x semana, 40 minutos, com guia), deficiente visual, dislipidêmico e epiléptico. Paciente foi submetido à cirurgia de reimplante de artéria coronária direita (ACD) em 2015, com de anomalia ACD com trajeto interarterial em avaliação pré-participação (APP). Evoluiu assintomático, em acompanhamento anual. Em 2017, pioraram os parâmetros eletrocardiográficos, sem sintomas. Encaminhado à cintilografia miocárdica (CM) com estresse físico, sem alteração perfusional. Em janeiro de 2019, após APP, realizou teste ergométrico, com intensificação de infradesnivelamento de segmento ST, abrangendo outras derivações. Diante disso, realizou angiotomografia de coronárias (ATC), que evidenciou kiking em óstio de ACD com sinais de compressão extrínseca e submetido a CM com dobutamina para avaliação de isquemia. REVISÃO: Apesar da baixa incidência na população geral, anomalia coronária é a segunda causa cardiovascular de morte súbita (MS) em atletas jovens, ocorrendo em ± 15 a 20 dos casos. O risco de MS em atletas com origem anômala é 79 vezes maior do que em não atletas. ACD originada no seio coronariano esquerdo é encontrada em 0,03 a 0,17 dos indivíduos submetidos à angiografia. Os sintomas mais frequentes são dor torácica atípica, dispneia, síncope ou pré-síncope relacionada ao exercício, arritmias e disfunção ventricular esquerda, mas na maioria das vezes assintomáticos. ATC e ressonância magnética são considerados padrão ouro para demonstrar a anatomia coronariana e Ecocardiograma transesofágico pode ser útil na avaliação de origem de coronárias, sem avaliação dos seus trajetos. O conhecimento das opções de tratamento e suas complicações são necessários para adequar o protocolo de imagem ao caso clínico. A avaliação da perfusão miocárdica com estresse contribui para estratificação de risco e tomada de decisão para retornar às atividades, porém seu papel na previsão do risco futuro de SCA é incerto. (AU)

Effects of four antiplatelet/statin combined strategies on immune and inflammatory responses in patients with acute myocardial infarction undergoing pharmacoinvasive strategy: Design and rationale of the B and T Types of Lymphocytes Evaluation in Acute Myocardial Infarction (BATTLE-AMI) study: study protocol for a randomized controlled trial.

BACKGROUND: Early reperfusion of the occluded coronary artery during acute myocardial infarction is considered crucial for reduction of infarcted mass and recovery of ventricular function. Effective microcirculation and the balance between protective and harmful lymphocytes may have roles in reperfusion injury and may affect final ventricular remodeling. METHODS/DESIGN: BATTLE-AMI is an open-label, randomized trial comparing the effects of four therapeutic strategies (rosuvastatin/ticagrelor, rosuvastatin/clopidogrel, simvastatin plus ezetimibe/ticagrelor, or simvastatin plus ezetimibe/clopidogrel) on infarcted mass and left ventricular ejection fraction (LVEF) (blinded endpoints) in patients with ST-segment elevation myocardial infarction submitted to fibrinolytic therapy before coronary angiogram (pharmacoinvasive strategy). All patients (n = 300, 75 per arm) will be followed up for six months. The effects of treatment on subsets of B and T lymphocytes will be determined by flow-cytometry/ELISPOT and will be correlated with the infarcted mass, LVEF, and microcirculation perfusion obtained by cardiac magnetic resonance imaging. The primary hypothesis is that the combined rosuvastatin/ticagrelor therapy will be superior to other therapies (particularly for the comparison with simvastatin plus ezetimibe/clopidogrel) for the achievement of better LVEF at 30 days (primary endpoint) and smaller infarcted mass (secondary endpoint) at 30 days and six months. The trial will also evaluate the improvement in the immune/inflammatory responses mediated by B and T lymphocytes. Omics field (metabolomics and proteomics) will help to understand these responses by molecular events. DISCUSSION: BATTLE-AMI is aimed to (1) evaluate the role of subsets of lymphocytes on microcirculation improvement and (2) show how the choice of statin/antiplatelet therapy may affect cardiac remodeling after acute myocardial infarction with ST elevation. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02428374 . Registered on 28 September 2014.

Uso racional dos exames diagnósticos em cardiologia / Rational use of diagnostic exams in cardiology

O cardiologista dispõe hoje de um amplo arsenal de exames diagnósticos, cada um baseado em diferentes princípios físicos e que tentam atender às necessidades da prática clínica. A falta de trabalhos comparativos entre eles em muitos cenários clínicos pode gerar incertezas quanto à real utilidade de cada um e pode levar à subutilização desses exames, mesmo quando eles são indicados, ou a seu emprego indiscriminado e exagerado. A ecocardiografia pode avaliar a função ventricular e a morfologia cardíaca em casos de cardiopatias congênitas, valvopatias e cardiomiopatias. A ressonância pode complementar esse exame e até ser o único método empregado em casos de coartação da aorta, bem como pode ter grande utilidade na identificação etimológica das cardiomiopatias. Já a medicina nuclear tem seu grande uso na identificação da isquemia miocárdica e a tomografia é fundamental no planejamento do tratamento percutâneo da estenose aórtica, assim como tem sido um exame de grande utilidade em diferentes estágios de doença coronariana. Este artigo tem o objetivo de rever as principais evidências disponíveis em cada condição clínica e apresentar uma sugestão do uso racional e eficaz dos exames de imagem em cardiologia

The cardiologist today has an extensive arsenal of diagnostic exams, each based on different physical principles, aimed at meeting the demands of clinical practice. The lack of comparative works on these exams in many clinical scenarios may generate uncertainties as to the real usefulness of each one, and can lead to their underuse, even when they are indicated, or to their indiscriminate and exaggerated use. Echocardiography can evaluate ventricular function and cardiac morphology in cases of congenital cardiopathies, valvopathies and cardiomyopathies. Magnetic resonance imaging can complement this exam, and may even be the only method used in cases of coarctation of the aorta. It may also be very useful in the etymological identification of cardiomyopathies. Nuclear medicine, meanwhile, is useful in identifying myocardial ischemia, and tomography is fundamental in the planning of percutaneous treatment of aortic stenosis, as well as having been a very useful exam in different stages of coronary disease. The aim of this article is to review the main evidence available in each clinical condition, and to present a suggestion for rational and effective use of imaging exams in cardiology

Effects of four antiplatelet/statin combined strategies on immune and inflammatory responses in patients with acute myocardial infarction undergoing pharmacoinvasive strategy: Design and rationale of the B and T types of lymphocytes evaluation in acute myocardial infarction (BATTLE-AMI) study: study protocol for a randomized controlled trial

BACKGROUND: Early reperfusion of the occluded coronary artery during acute myocardial infarction is considered crucial for reduction of infarcted mass and recovery of ventricular function. Effective microcirculation and the balance between protective and harmful lymphocytes may have roles in reperfusion injury and may affect final ventricular remodeling. METHODS/DESIGN: BATTLE-AMI is an open-label, randomized trial comparing the effects of four therapeutic strategies (rosuvastatin/ticagrelor, rosuvastatin/clopidogrel, simvastatin plus ezetimibe/ticagrelor, or simvastatin plus ezetimibe/clopidogrel) on infarcted mass and left ventricular ejection fraction (LVEF) (blinded endpoints) in patients with ST-segment elevation myocardial infarction submitted to fibrinolytic therapy before coronary angiogram (pharmacoinvasive strategy). All patients (n = 300, 75 per arm) will be followed up for six months. The effects of treatment on subsets of B and T lymphocytes will be determined by flow-cytometry/ELISPOT and will be correlated with the infarcted mass, LVEF, and microcirculation perfusion obtained by cardiac magnetic resonance imaging. The primary hypothesis is that the combined rosuvastatin/ticagrelor therapy will be superior to other therapies (particularly for the comparison with simvastatin plus ezetimibe/clopidogrel) for the achievement of better LVEF at 30 days (primary endpoint) and smaller infarcted mass (secondary endpoint) at 30 days and six months...

Treatment of patients with aortic atherosclerotic disease with paclitaxel-associated lipid nanoparticles.

OBJECTIVE: The toxicity of anti-cancer chemotherapeutic agents can be reduced by associating these compounds, such as the anti-proliferative agent paclitaxel, with a cholesterol-rich nanoemulsion (LDE) that mimics the lipid composition of low-density lipoprotein (LDL). When injected into circulation, the LDE concentrates the carried drugs in neoplastic tissues and atherosclerotic lesions. In rabbits, atherosclerotic lesion size was reduced by 65% following LDE-paclitaxel treatment. The current study aimed to test the effectiveness of LDE-paclitaxel on inpatients with aortic atherosclerosis. METHODS: This study tested a 175 mg/m2 body surface area dose of LDE-paclitaxel (intravenous administration, 3/3 weeks for 6 cycles) in patients with aortic atherosclerosis who were aged between 69 and 86 yrs. A control group of 9 untreated patients with aortic atherosclerosis (72-83 yrs) was also observed. RESULTS: The LDE-paclitaxel treatment elicited no important clinical or laboratory toxicities. Images were acquired via multiple detector computer tomography angiography (64-slice scanner) before treatment and at 1-2 months after treatment. The images showed that the mean plaque volume in the aortic artery wall was reduced in 4 of the 8 patients, while in 3 patients it remained unchanged and in one patient it increased. In the control group, images were acquired twice with an interval of 6-8 months. None of the patients in this group exhibited a reduction in plaque volume; in contrast, the plaque volume increased in three patients and remained stable in four patients. During the study period, one death unrelated to the treatment occurred in the LDE-paclitaxel group and one death occurred in the control group. CONCLUSION: Treatment with LDE-paclitaxel was tolerated by patients with cardiovascular disease and showed the potential to reduce atherosclerotic lesion size.